IgA nephropathy is one of the most common primary glomerular diseases worldwide, particularly common in China and East Asian countries. Most patients exhibit slow progression of kidney disease, which is the most common cause of end-stage kidney disease in young people and imposes a heavy disease burden on families and society【1】. In the treatment process of IgA nephropathy, patient education is an important link, and currently there is still significant room for improvement and unmet needs in the disease cognition and self-management abilities of IgA nephropathy patients. In order to help more IgA nephropathy patients acquire diagnosis and treatment knowledge and improve their disease management abilities, the “Defend Kidney Function – IgA Kidney Friends Hundred City Public Welfare Tour” project Changsha station activity was held at the Wuyi Road branch of Tat Ka Wai Hong Pharmacy. Through a combination of online and offline kidney education activities, doctor-patient interaction, and science popularization dissemination, it promotes early diagnosis and treatment of patients, thereby delaying disease progression and improving quality of life.
Hou Jia, Chairman of Changsha Kidney Charity Service Center, delivered a speech on site, sharing the practical experience of public welfare forces in early screening for kidney disease, patient education, and psychological support.
This event invited Professor Liu Jishi from the Department of Nephrology at Xiangya Third Hospital of Central South University to give a keynote lecture, using real cases to explain the symptoms, dietary principles, and medication treatment plans of IgA nephropathy. We encourage everyone to have a correct understanding of the disease and achieve early diagnosis, treatment, and peace of mind.
During the on-site Q&A session, Professor Liu Jishi answered each question that patients were concerned about one by one. Regarding the issue of budesonide enteric coated capsules that many kidney enthusiasts are concerned about, Professor Liu answered: Budesonide enteric coated capsules (Naifukang) ® NEFECON ®） It is the world’s first targeted therapy for IgA nephropathy at its source – intestinal mucosal immunity, and the first innovative drug approved by the three authoritative drug regulatory agencies of the US FDA, European EMA, and Chinese NMPA for the treatment of IgA nephropathy【2-7】. It has significant clinical significance. It is suitable for adult patients with primary IgA nephropathy at risk of progression, which can reduce renal function loss, lower proteinuria, and improve hematuria. Budesonide enteric coated capsules (Naifukang) ® NEFECON ®） Available at Tat Ka Wai Hong Pharmacy, we actively cooperate with clinical needs and timely and securely deliver drugs to where patients need them.
List of DTP Pharmacy Information for Tat Ka Wai Hong
Reference:
1.The application of new drugs and the transformation of treatment strategies are expected to improve the prognosis of IgA nephropathy patients [J]. Chinese Medical Information Review, 2024, 39 (16): 11. DOI: 10.3760/cma/j.issn.1000-8039.2024.16.118
2.https://www.nmpa.gov.cn/zwfw/sdxx/sdxxyp/yppjfb/20231124144653113.html.
3.FDA approves first drug to decrease urine protein in IgA nephropathy, a rare kidney disease
4.https://news.cision.com/calliditas-therapeutics/r/european-commission-approves-kinpeygo–for-adults-with-primary-iga-nephropathy , c3600434.
5.https://www.calliditas.se/en/calliditas-therapeutics-announces-full-fda-approval-of-tarpeyo-the-only-fda-approved-treatment-for-iga-nephropathy-to-significantly-reduce-the-loss-of-kidney-function/
6.https://www.everestmedicines.com/zhhans/news/yundingxinyaohezuohuobancalliditasxuanbunaifukanghuodemeiguofdawanquanpizhunyongyuzhiliaoyoujinzhanfengxiandeigashenbinghuanzhe-wulunqijixiandanbainiaoshuiping/936f18ac-566a-4b3d-8cd0-036f720b62e6/
7.https://news.cision.com/calliditas-therapeutics/r/european-commission-approves-kinpeygo–for-adults-with-primary-iga-nephropathy,c3600434.